Commentary As reported in a handful of media outlets, Pfizer and Moderna’s new trials closely investigating vaccine myocarditis are underway. As part of its vaccine approval, the FDA has mandated (pdf) both companies to conduct clinical trials tracking vaccine myocarditis months and years beyond diagnosis.
As NBC reports, “Moderna has already launched two trials, the most recent in September. Pfizer confirmed that at least one of its trials, which will include up to 500 teens and young adults under age 21, is slated to begin in the next couple of months.”
As has been long-established, mRNA vaccines induce myocarditis at alarmingly high rates in young men. A new study published in the Journal of the American College of Cardiology compares rates of myocarditis between the Pfizer and Moderna vaccine. It finds a vaccine myocarditis rate of 1 in 3,636 in men ages 18 to 29 following a second dose of the Moderna vaccine. For Pfizer, the authors report a rate of 1 in 20,000 in the same age group—roughly equal to the rate for Moderna in men ages 30 to 39….